April 25, 2018 9:26 AM ET

Healthcare Equipment and Supplies

Company Overview of I-MED Pharma, Inc.

Company Overview

I-MED Pharma, Inc. manufactures and distributes products for the surgical, medical, and veterinary ophthalmic communities. It offers various products, including anterior lamellar keratoplasty, corneal transplants, penetrating keratoplasty, dry eye solutions, descemets stripping automated endothelial keratoplasty, glaucoma treatment solutions, corneal implants, intraocular lenses, refractive surgery, reusable and disposable, sterilization boxes, surgical instruments, and viscoelastics for human use. The company also provides veterinary products, including dry eye drops, bio-erodable ophthalmic corneal shields, corneal protective shields, capsular tension rings, ophthalmic viscoelastic devices...

1601 St. Régis Boulevard

Dollard-des Ormeaux, QC H9B 3H7






Key Executives for I-MED Pharma, Inc.

I-MED Pharma, Inc. does not have any Key Executives recorded.

I-MED Pharma, Inc. Key Developments

TearLab Corporation Plans to Appeal Recent Ruling from the Federal Court of Canada Related to its Single Canadian Patent

TearLab Corporation announced its plans to appeal a recent ruling from the Federal Court of Canada related to its single Canadian patent. TearLab initiated the lawsuit against I-Med Pharma and its i-Pen Osmolarity System in the Federal Court of Canada during February 2016. In the ruling published on February 14, 2018, the court found that the i-Pen did indeed infringe the TearLab patent; however, specific claims in the patent were deemed by the trial judge to be invalid. TearLab will appeal the finding of invalidity.

I-MED Pharma, Inc. Partners with OCuSOFT, Inc. to Bring the I-Pen® Osmolarity System to USA

I-MED Pharma Inc. announced the signing of an exclusive agreement with OCuSOFT Inc. for distribution rights in the United States for its patented I-PEN® Osmolarity System.  This distribution partnership will officially commence upon final FDA approval of the 510,000, which is anticipated in the first quarter of 2018.

I-MED Pharma, Inc. Announces I-PEN®, I-DROP® and I-PLUG® Available in Spain and Portugal Through Partnership with IMEX

I-MED Pharma, Inc. announced the signing of an exclusive agreement with IMEX for distribution of it’s I-PEN® Tear Osmolarity System, I-DROP® viscoadaptive dry eye drops, I-PLUG® punctum plugs, as well as other dry eye products for Spain and Portugal.

Similar Private Companies By Industry

Company Name Region
7D Surgical, Inc. Americas
A.R. Medicom, Inc. Americas
ABK Biomedical Inc. Americas
AceAge Inc. Americas
Adaptaide Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact I-MED Pharma, Inc., please visit www.imedpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.